BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test, a comprehensive integrated genomic and transcriptomic analysis of tumors and the microenvironment, reveals key drivers of each tumor. This company was founded in 2015 by Andrew Feinberg and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/06/2022 | Series B | $150MM | $xx.xx | $205.25B | Impact Investment Capital, Japan Industrial Partners, Nec Corporation | |
Price per Share
$xx.xx
Shares Outstanding
32,999,670
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Impact Investment Capital, Japan Industrial Partners, Nec Corporation
|
||||||
04/24/2019 | Series A | $50MM | $xx.xx | $33.33B | Nec Corporation | |
Price per Share
$xx.xx
Shares Outstanding
50,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nec Corporation
|